Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

BACKGROUND. Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) that inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. METHODS. We used stable isotopic labeling with deuterated water ((2)H(2)O) to measure directly the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Burger, Jan A., Li, Kelvin W., Keating, Michael J., Sivina, Mariela, Amer, Ahmed M., Garg, Naveen, Ferrajoli, Alessandra, Huang, Xuelin, Kantarjian, Hagop, Wierda, William G., O’Brien, Susan, Hellerstein, Marc K., Turner, Scott M., Emson, Claire L., Chen, Shih-Shih, Yan, Xiao-Jie, Wodarz, Dominik, Chiorazzi, Nicholas
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2017
Témata:
Clinical Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256142/
https://ncbi.nlm.nih.gov/pubmed/28138560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.89904
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky